Expression of a marker for colonic crypt base cells is correlated with poor prognosis in human colorectal cancer

A A M van der Wurff, J ten Kate, P T J Marx, E P M van der Linden, C C L Beek, F-J Bovelander, J Dekker, W N M Dinjens, M F von Meyenfeldt, J-W Arends, F T Bosman

Abstract

Background—There is a need for markers in colorectal cancer which will allow subclassification of stage groups into subgroups with high versus low risk of recurrent disease.

Aims—To develop monoclonal antibodies that recognise antigens on immature crypt base cells, on the assumption that in a neoplasm undifferentiated but not the terminally differentiated cells will be responsible for tumour progression.

Methods—Colon crypt cells which were isolated from human colon mucosa by EDTA/EGTA incubation were studied. By stepwise harvesting, crypt base cell enriched fractions were obtained, and after incubation with antibodies against dominant antigens, used as immunogens.

Results—Of one crypt base cell specific antibody (5E9), the reactive epitope appeared to be a non-terminal carbohydrate in the mucin O-glycans of the colon. The epitope did not seem to be colon specific, but was expressed in a variety of other tissues. In colorectal carcinomas, 5E9 immunoreactivity identified a subgroup of patients with a tendency for worse prognosis.

Conclusion—A mucin associated maturation epitope was identified in colonic crypt base cells, the expression of which in Dukes’ stage B3 colorectal carcinoma can be associated with poor prognosis.

(Gut 1998;42:63–70)

Keywords: colorectal adenocarcinoma; maturation epitope; stem cell; prognostic marker; mucin

In colorectal cancer, tumour stage as expressed in the Dukes’ classification is still one of the best prognostic indicators. However, the behaviour of individual tumours within a stage is not uniform and therefore additional prognostic factors are needed for more accurate determination of tumour behaviour. One such prognostic indicator is histological grading which is, however, subjective and of limited significance.

In search for independent prognostic indicators, in addition to proliferation, oncogene status and ploidy, differentiation markers have been developed for the cell lineages in the colonic epithelium, which include columnar cells, mucin producing goblet cells, and neuroendocrine cells. In a large series of colorectal adenocarcinomas, markers for end stages of differentiation did not seem to have prognostic value. Only neuroendocrine markers correlated with worse prognosis which might reflect the relative immaturity of these cells, which are located basally in the crypt.

All colonic epithelial cells are thought to arise from a common progenitor cell, the stem cell, which is located at the bottom of the crypt and gives rise to daughter cells with proliferative capacity. During movement upwards in the direction of the lumen, the proliferative ability of the committed precursor cells for each of the three cell lineages is lost and gradual differentiation takes place. The fully differentiated cells are eventually shed into the bowel lumen.

For normal large bowel mucosa the stem cell concept appears valid and has gained wide acceptance. For carcinomas several observations support this concept. Firstly, in a small proportion of colorectal carcinomas a wide spectrum of differentiatation has been found. These findings are strongly in favour of the origin of these tumours from a multipotential stem cell and these “stem cell” carcinomas seem to have a particularly unfavourable prognosis. Secondly, in colon cancer cell lines induction of differentiation reduces the proliferative index. Finally, studies on human colon cancer cell lines have shown that these may exhibit a variable degree of proliferative activity, clonogenic potential, and cell differentiation. Finally, clonogenic assays generally show cloning efficiencies of tumour cell populations as low as 0.001%, suggesting that the proliferating tumour cell fraction in human tumours is small.

Our working hypothesis is that in analogy with normal colonic mucosa, in colorectal cancer tumour stem cells exist. The proliferative capacity and stage of maturation of the tumour stem cells would be an important determinant of tumour behaviour: the more immature the tumour stem cell, the higher the proliferation index and the less differentiated and the more aggressive the tumour. To test the validity of this concept, we set out to generate monoclonal antibodies, which selectively stain crypt base cells, assuming that antigens in immature crypt base cells might also be expressed in colonic adenocarcinomas. In this paper, we describe the generation and characterisation, by way of immunohistochemistry, immunochemical, and biochemical analysis, of a new monoclonal...
antibody, 5E9, which selectively stains goblet cells in the lower half of the colonic crypt. The prognostic significance of its immunoreactivity was tested on a large series of colorectal adenocarcinomas. High expression of the 5E9 epitope appeared to be correlated with a tendency for poor prognosis in patients with Dukes’ stage B3 cancer.

Materials and methods

MONOCLONAL ANTIBODY PRODUCTION

As a source of colon crypt epithelial cells, we used mucosa from neonatal as well as non-neonatal colectomy specimens. In specimens resected because of cancer, mucosa at a distance of at least 5 cm from the tumour was used. This was incubated, after decontamination with 0.04% (mass/volume) sodium hypochlorite in phosphate buffered saline (PBS) and 0.5 mmol/l dithiothreitol (DTT) in PBS to free the sample of mucus, with 0.05 mmol/l EDTA in calcium and magnesium free Hanks balanced salt solution (CMF-HBSS, Gibco, Paisley, Scotland) in a spinner flask (Gibco) according to ten Kate et al.23 The mucosa with the remaining crypt bottom parts was incubated according to Whitehead et al24 in a sterile petri dish containing 1 mmol/l EDTA (Merek, Darmstadt, Germany), 1 mmol/l ethylendiglycol-bis-(β-aminoethyl ether)N,N’-tetra-acetic acid (EGTA, Sigma Chemical Company, St Louis, Missouri, USA), and 0.5 mmol/l DTT (Sigma) in PBS (pH 7.4), for 30 minutes at room temperature. The crypts were liberated by vigorous shaking and harvested by centrifugation. The cells were lysed in buffer containing 5 mmol/l NaHPO₄, 1 mmol/l EDTA, 1 mmol/l β-mercaptoethanol, 0.125% (mass/mass) deoxycholate, 0.125% (vol/vol) Triton X-100, and 250 mmol/l sucrose (pH 7.8) and stored in a sucrose buffer of 0.1 mol/l HCl, pH 7.8 and pepsin (0.1 mol/l HCl). Pronase in 0.05 mol/l Tris HCl (pH 8) was also tested in concentrations of 0.04% to 0.0025% (mass/vol) at 37°C. Immunoperoxidase staining was performed using rabbit antiamouse IgG conjugated to horseradish peroxidase (HRP) as the detection system and diaminobenzidine (DAB)-H₂O₂ as the chromogenic substrate. For postembedding immunoelectron microscopy, 1 mm³ fragments of human colon mucosa taken from freshly obtained surgical specimens were fixed in 0.1 mol/l phosphate buffer (pH 7.2) containing 1% (mass/vol) acroleine and 0.4% (mass/vol) glutaraldehyde at 4°C for four hours. Tissues were transferred and stored in a sucrose buffer of 1 mol/l sucrose in 0.1 mol/l phosphate buffer (pH 7.2) with 1% (vol/vol) paraformaldehyde at 4°C until further processing for standard Lowicryl embedding.25 After impregnation of the tissues with Lowicryl K4M (Baltzers, Liechtenstein) polymerisation was performed under ultraviolet exposure at –35°C. Ultrathin sections were incubated first with 10% (vol/vol) normal goat serum (NGS, Dakopatts, Glostrup, Denmark) in PBS (30 minutes at room temperature), second with primary antibodies (one hour at room temperature), and finally with 10 nm colloidal gold labelled goat antimouse antiserum (GAM-10, Aureon, Wageningen, The Netherlands) under microwave irradiation at 150 W for 30 minutes.26 The immunogold–silver enhancement was done by magnification of the gold particles by precipitation of metallic silver (Aureon R Gent Developer and Enhancer, applied for two minutes at room temperature in the dark; Aureon). After rinsing in distilled water the sections were dried. The sections were contrasted with uranyl acetate and lead citrate. Micrographs were taken on a Zeiss EM 902 at 80 kV. Control sections were incubated with PBS. Background staining was always negligible.

BIOCHEMICAL CHARACTERISATION

A polyclonal antiserum was raised against human colonic mucin as described previously (anti-HCM).30 The characterisation of the mucin epitopes recognised by 5E9 was performed by western and blotting of purified colonic mucin, as described earlier for rat gastric mucin.31 Briefly, purified mucins were either run on 4% sodium dodecyl sulphate polyacrylamide gels and blotted onto nitrocellulose, or purified
mucins were spotted directly on nitrocellulose using a vacuum operated spot blot apparatus (Biorad, Richmond, USA). Blots were incubated either with anti-HCM (for reasons of comparison) or spent 5E9 hybridoma culture medium, diluted 1/100, followed by incubation with goat antirabbit IgG conjugated to HRP and stained with DAB. Specificity for peptide and carbohydrate epitopes was tested separately as follows:

1. Proteinase K sensitivity prior to spot blotting (to determine the possible peptide nature of the epitope).
2. Epitope sensitivity towards DTT reduction (to determine whether or not 5E9 detects conformational peptide epitope).
3. Oxidative destruction of carbohydrate epitopes by periodic acid (to determine the carbohydrate nature).
4. Incubation of 5E9 with the protease resistant glycopeptide of HCM (as an alternative method to show reactivity towards carbohydrate epitopes). To this end, HCM was digested for 24 hours with 10 µg/ml proteinase K (Merck) in 50 mM Tris, pH 7.4, at 37°C. The proteinase K was inactivated by addition of an excess of phenylmethylsulphonyl fluoride (Sigma). The proteinase resistant glycopeptide was subsequently recovered in the void volume after Sephadryl S-200 (Pharmacia) gel filtration in 50 mM Tris, pH 7.5. Isolated HCM glycopeptide was incubated for one hour at room temperature with the antibody prior to addition to the spot blotted mucin.

The recognition of mucin antigens was further tested in metabolic labelling experiments of colonic biopsy samples followed by immunoprecipitation of radiolabelled mucins, as described in detail elsewhere.30 To test whether the epitope recognised by 5E9 is a sialylated carbohydrate chain, neuraminidase digestion was performed according to Jass et al21; 1 mg neuraminidase (Clostridium perfringens, Fluka 72202, Lot 326138/1) was dissolved in 0.425 ml of 0.05 M Tris HCl buffer, pH 7.0, containing 0.01% (wt/vol) CaCl₂. Saponification was achieved by immersing the slides in 0.5% KOH in 70% (vol/vol) alcohol (30 minutes at room temperature). Thereafter the slides were rinsed in 70% (vol/vol) alcohol and washed in tap water for 10 minutes. As a positive control the lectin PNA (Boehringer Mannheim) was used with and without saponification.

STATISTICAL ANALYSIS

Colorectal adenocarcinomas of 350 patients were entered into two multicentre prospective clinical trials between 1979 and 1981. One trial was designed to compare patient survival after treatment of colonic cancer by conventional surgery or the no touch isolation technique.33 The other trial was conducted to compare survival in rectal cancer patients with or without preoperative radiotherapy. These patient series did not differ in overall survival; therefore, for the purpose of the present study, the patient groups were pooled. During the first three years follow up took place every three months; between three and five years after the initial diagnosis and surgery follow up was every six months. Standard protocols were conducted with routine blood counts and biochemistry studies (including carcinoembryonic antigen levels) at each visit and liver ultrasound, chest x ray, and colonoscopy annually, to evaluate recurrence of disease and disease related death. After the initial five year follow up, during subsequent years only the time and cause of death were registered. In this study, failure was defined as death due to recurrent disease, excluding postoperative mortality within 30 days and non-related death. The correlation between monoclonal antibody 5E9 expression and other colorectal differentiation markers, Dukes’ stage, differentiation grade, tumour size, localisation of the tumour within the large intestine, presence of (lymph) angioinvasion or perineural invasion, lymph node status, and central lymph node involvement was investigated in two way frequency tables using BMDP PC90 Statistical Software, program 4F (BMDP Statistical Software, Inc., Los Angeles, California). Interdependency of 5E9 expression and these variables was tested with Pearson’s χ² method. Scoring was done by two independent investigators and 5E9 expression was compared with markers for the colorectal epithelial cell lineages. Mucin production was detected with the monoclonal antibody Parlax 3,23 which detects a glycoprotein present in normal goblet cells and with the high iron diamine alcian blue (HID-AB) technique, which stains sulphated mucins brown. Cular cells were identified by immunoreactivity for secretory component (SC). Neuroendocrine differentiation was detected with a monoclonal antibody against chromogranin A, the major component of neurosecretory granules.

As a clinicopathological staging system we used the Dukes’ classification.1 Differentiation grade was assessed according to criteria outlined by Blenkinsopp et al.2 The prognostic value of 5E9 expression with respect to survival was investigated by univariate analysis, using Kaplan-Meier estimations and the stratified log rank test, with the program 4F, BMDP PC90 Statistical Software. To exclude the possibility of a type I error in the statistical analysis, a Bonferroni test was also performed.

Results

IMMUNOHISTOCHEMISTRY OF THE MONOCLONAL ANTIBODY 5E9

With the described immunisation protocol, the IgM κ monoclonal antibody 5E9 was obtained, staining goblet cells located at the crypt base of normal colorectal epithelium (fig 1A). For immunohistochemical experiments at light microscopical level, immunostaining on standard paraffin wax embedded tissue with spent hybridoma supernatant was optimal in a dilution of 1/50 in PBS–1% bovine serum albumin (BSA), after enzyme digestion of the tissue sections with 0.01% pepsin in 0.1 mol/l HCl (15 minutes at 37°C). Comparison of unfixed cryostat sections with paraffin wax
sections after pepsin treatment showed an identical staining pattern for both conditions. Figures 1 and 2 show the immunoreactivity pattern of the monoclonal antibody 5E9 in normal and malignant human tissues. Normal mucosa from neoplastic as well as non-neoplastic colectomy specimens (proximal and distal colon) was used. To exclude the possibility that 5E9 recognizes a major blood group antigen we stained colon mucosa samples from patients with different ABO blood groups. In all groups an identical staining pattern was obtained. In the digestive tract, immunoreactivity was noted in submucosal glands of the oesophagus, duct epithelium of the parotid gland, goblet cells at the lower half of the crypt in the duodenum, some pancreatic duct cells (fig 1B), and in the mucosa lining the gall bladder (fig 1C). Pancreatic islets were not stained. In normal colonic mucosa, from neoplastic as well as non-neoplastic resection specimens, only crypt base cells showed 5E9 immunoreactivity. Strikingly, immunoreactivity was observed in all goblet cells in colonic epithelium adjacent to adenocarcinomas (transitional mucosa, fig 1D). In the stomach, reactivity was noted only in some goblet cells in areas of intestinal metaplasia (fig 1E). In the urogenital tract, staining was observed in endometrial and endocervical glandular epithelium (fig 1F). Furthermore, reactivity was found in some acinar and duct cells of the breast. Focal reactivity was also observed in prostate and bladder epithelium. In normal ovary tissue, no immunoreactivity was found. In cystadenomas and adenocarcinomas of the ovary, however, whether serous or mucinous, focal immunoreactivity was noted. In the respiratory tract, bronchial epithelium, pneumocytes type II and few goblet cells in the lining tracheal epithelium showed staining. Carcinomas in urogenital and respiratory tract showed mostly a focal immunoreactivity pattern.

Colorectal adenocarcinomas showed 5E9 immunoreactivity in 33% of our 297 cases. The proportion of positive cases did not differ appreciably for different periods of collection of patient material, which makes it unlikely that variations in tissue preparation techniques or

Figure 1 Immunoreactivity pattern of the monoclonal antibody 5E9 on various normal human tissues: (A) normal colonic mucosa; (B) pancreas; (C) gall bladder; (D) transitional colonic mucosa; (E) intestinal metaplasia in the stomach; (F) cervix uteri: squamocolumnar junction.
limited antigen stability might have influenced the immunohistochemical results. The staining was often intracellular, but also apical membrane associated; some single cells were frequently homogeneously stained, but occasionally diffuse staining was observed (fig 2). By immunoelectron microscopy the reactivity was located intracellularly on the outer rim of mucin vacuoles (fig 3). Staining of the Golgi complex was not observed.

BIOCHEMICAL CHARACTERISATION OF THE 5E9 EPITOPE
As colonic mucosa was used as antigen source, mucins seemed to be the likely candidates for the antigen recognised by 5E9. Therefore, studies were undertaken to define this antigen, using purified HCM for comparison. Previous studies had shown that anti-HCM specifically recognises polypeptide epitopes of Muc2.30 On western blotting, HCM was recognised by both anti-HCM and 5E9 as a 550 kDa band. This band was previously identified as human colonic Muc2, the major secretory mucin in the colon, which is produced in the colonic goblet cells.30 Digestion with proteinase K resulted in a decrease in the immunoreactivity of 5E9 towards HCM, while reduction by DDT had no effect. Oxidation of carbohydrate epitopes by periodic acid resulted in complete loss of reactivity. Furthermore, preincubation with HCM glycopeptide had no effect on reactivity. These results indicate that 5E9 most likely recognises a carbohydrate epitope of HCM. In metabolic labelling studies using 5E9, we were unable to immunoprecipitate 35S sulphate labelled mature Muc2, or its 35S amino acid labelled precursor. As a positive control, immunoprecipitations from the same tissue homogenates, using anti-HCM, yielded the expected 600 kDa 35S amino acid labelled Muc2 precursor, and the 550 kDa 35S sulphate labelled mature Muc2.

5E9 immunoreactivity could not be abolished by neuraminidase digestion with or without prior saponification. Lectin PNA, used as a positive control, showed the expected reactivity pattern.

CLINICOPATHOLOGICAL ANALYSIS
The 350 patients in this study were 165 men and 185 women, ranging in age from 29 to 91 years (median age 69 years). 5E9 staining was performed on available tissue specimens of 297 patients (192 colonic adenocarcinomas and 105 rectal carcinomas). These were comparable in Dukes’ stage and histological grading to the overall population. To obtain subgroups suitable for statistical analysis, the subgroups were combined: group A tumours consisted of colorectal adenocarcinomas of Dukes’ stage A, B1, and B2; group B consisted of Dukes’ stage B3; group C combined Dukes’ stage C1 and C2 tumours; and group D contained Dukes’ stage D. Of the tumours, using the above mentioned Dukes’ combinations, 63 were group A, 117 group B, 91 group C, and 26 group D. The number of well differentiated tumours was 31; 227 tumours were moderately differentiated and 32 poorly differentiated (seven tumours...
Discussion

The histological classification of colorectal adenocarcinoma has not changed in recent years. In addition to adenocarcinomas, mucinous, signet ring, and undifferentiated carcinomas are distinguished (World Health Organisation). Furthermore, grading is performed in a three grade system, which falls short in reproducibility and has limited prognostic significance. Various attempts have been made to improve classification using markers for end differentiation stages of the cell lineages in colonic epithelium.

Secretory component (SC) is a marker for enterocytes, lysozyme is a marker for Paneth cells, different mucin markers identify goblet cells, and neuroendocrine markers identify neuroendocrine cells. Mucins, SC, and lysozyme are often coexpressed in a large proportion of the adenocarcinomas and for these markers a consistent prognostic significance has not been reported. With regard to neuroendocrine markers, expression of chromogranin A was repeatedly found to correlate significantly with worse prognosis.

In looking for new markers for classification of colorectal cancer we reasoned that the behaviour of the tumour is largely determined by the proliferating stem cell fraction and not by terminally differentiated cells. Therefore, it would be plausible to look for markers for the undifferentiated (stem) cell fraction of the tumour. In the search for such markers we reasoned that crypt base cell associated antigens might also identify immature tumour (stem) cells.

Using as an antigen source epithelium of crypt bases, which was incubated with antibodies against major mucin epitopes and with sera against colonic epithelium generated in mice to block for dominant epitopes, we succeeded in developing an antibody against a subset of goblet cells located in the lower half of the crypt, around and just above the proliferation zone. The epitope of this monoclonal antibody is expressed in a diversity of human tissues, both normal and malignant, but shows a very specific staining pattern in the colon. Immunoelectron microscopy showed reactivity in the outer rim of mucin vacuoles in goblet cells. It is of interest that in the digestive tract 5E9 staining was found in goblet cell in intestinal metaplasia in gastric mucosa as well in Barrett’s oesophagus. Both conditions carry an increased risk for the development of adenocarcinoma. In contrast to staining of basally located goblet cells in normal colonic mucosa, all goblet cells were stained in transitional mucosa neighbouring adenocarcinoma. Ultrastructural studies have indicated that crypt epithelial cells in transitional mucosa show slower maturation than normal. The increase of 5E9 positive cells in transitional mucosa could be the result of such a delay in the process of crypt cell maturation and this observation would be in keeping with the lower differentiation level of 5E9 expressing goblet cells.

In the search for the epitope recognised by 5E9, immunoblotting showed that 5E9 recognises an epitope present on an HCM associated glycoprotein, identified as human colonic....
Colonic crypt base cell marker and poor prognosis

...The blocking of 5E9 staining by periodic acid oxidation and by preincubation with the HCM glycopeptide indicates that 5E9 recognises a carbohydrate (O-glycans) epitope on Muc2. Although the monoclonal antibody recognised Muc2 in blots, it was not able to retrieve the antigen by immunoprecipitation from homogenates. Possible explanations could be scarcity of the O-glycan epitope, the absence of an O-glycan in Muc2, or low density of this carbohydrate in Muc2. Although the monoclonal antibody reacted specifically with crypt base cells in blots, it was not able to retrieve the antigen by immunoprecipitation from homogenates. Possible explanations could be scarcity of the O-glycan epitope, the absence of an O-glycan in Muc2, or low density of this carbohydrate in Muc2.

...5E9 staining suggests that the Muc2 epitope, recognised by 5E9, becomes masked when the goblet cells differentiate further during their migration upward from the bottom of the crypt. This could imply that the O-glycosylation pattern of Muc2 changes when the crypt cells migrate upward. The epitope recognised by 5E9 seems not to be sialic acid given the insensitivity to neuraminidase treatment with or without prior saponification. In the literature other monoclonal antibodies such as SIMA and Stn, with a comparable immunoreactivity pattern, are described. These antibodies recognise sialylated carbohydrate chains. To evaluate the potential prognostic significance of 5E9 expression in colorectal adenocarcinomas, we stained a series of human colorectal carcinomas and compared the 5E9 status with various earlier studied pathological variables. We noted a trend towards 5E9 expression along with chromogranin A defined neuroendocrine and HID-AB defined sulphomucin expression. Both characteristics were earlier found to be associated with worse prognosis. The stratified log rank test did not yield any significance. In our group A (Dukes' stage A1, B1, and B2) and group C carcinomas (Dukes' stage C1 and C2), 5E9 staining did not have any prognostic significance. In Dukes' stage B3 patients, however, a group of patients with a heterogeneous chance of survival, 5E9 appeared to be a positive prognostic variable, identifying a subgroup of patients with a worse prognosis. This increased expression of the 5E9 epitope in prognostically unfavourable Dukes' stage B3 adenocarcinomas can indicate that a change in the O-glycosylation of Muc2 in colonic tumour cells might take place during progression towards recurrent (incurable) disease.

In conclusion, we have developed a new monoclonal antibody which most likely recognises a non-terminal carbohydrate epitope on the Muc2 O-glycans in the colon and which reacts specifically with crypt base cells in colonic mucosa. In group B, Dukes stage B3 adenocarcinomas, 5E9 staining identifies a subset of tumours with a tendency for worse prognosis. Studies on more cases are needed to show whether these results prove to be statistically significant. Also, the clinical value of 5E9 for classifying colorectal cancer needs to be evaluated further.

21 Salmon SE. Human tumor colony assay and chromosomeno-


